AbD Serotec and Merck Sign License Agreement for Use of HuCAL GOLD in Vaccine Research

Monday, 01. August 2011 07:30
MorphoSys AG /
AbD Serotec and Merck Sign License Agreement for Use of HuCAL GOLD in Vaccine
Research
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that its
research and diagnostic antibody unit AbD Serotec has amended its existing
license agreement with Merck & Co., Inc. to include the use of MorphoSys's HuCAL
GOLD technology in the field of vaccines. Under the terms of the agreement,
Merck is granted access to HuCAL GOLD for research purposes, with the option to
upgrade to MorphoSys's latest proprietary antibody library HuCAL PLATINUM.
MorphoSys's research and diagnostic antibody segment AbD Serotec will receive
annual user fees from Merck for access to the HuCAL technology and license fees
for clinical monitoring reagents. Further financial details were not disclosed.



"We welcome Merck's decision to continue using the HuCAL technology on the
research side as a tool to support their vaccine development activities. It is a
clear sign of the sustained interest of the pharmaceutical industry in our
leading antibody technology," commented Dieter Feger, Senior Vice President and
Head of AbD Serotec.



About MorphoSys:
MorphoSys is an independent biotechnology company that develops novel antibodies
for therapeutic, diagnostic and research applications. The Company's HuCAL
technology is one of the most powerful methods available for generating fully
human antibodies. By successfully applying this and other proprietary
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human health-care.
Through its alliances with some of the world's leading pharmaceutical companies,
MorphoSys has created a pipeline of more than 60 drug candidates. The Company is
expanding its drug pipeline by adding new partnered programs, and by building a
portfolio of fully-owned therapeutic antibodies. For its proprietary portfolio,
the Company is focused on the areas of oncology and inflammation. Its most
advanced program MOR103, a first-in-class, fully human antibody against GM-CSF,
is currently being tested in a Phase Ib/IIa trial in rheumatoid arthritis
patients. Via its business unit AbD Serotec, MorphoSys is expanding the reach of
its technologies in the diagnostics and research markets. MorphoSys is
headquartered in Munich, Germany and listed on the Frankfurt Stock Exchange
under the symbol "MOR". For further information, visithttp://www.morphosys.com/

About AbD Serotec:
AbD Serotec is one of the most reliable, complete sources of research and
diagnostic antibodies in the world. Easy On-line Ordering, With or Without
Credit Card, ISO-certified 2,200 Square Meter Production Facility, Your personal
AntibodyDetective, More Than 14,000 Catalog Antibodies, Custom Monoclonals in
Just 8 Weeks, Antibody Conjugation and Production.

HuCAL(®), HuCAL GOLD(®), HuCAL PLATINUM(®), CysDisplay(®), RapMAT(®) and
Slonimics(®) are registered trademarks of MorphoSys; arYla(TM) is a trademark of
MorphoSys.


This communication contains certain forward-looking statements concerning the
MorphoSys group of companies. The forward-looking statements contained herein
represent the judgment of MorphoSys as of the date of this release and involve
risks and uncertainties. Should actual conditions differ from the Company's
assumptions, actual results and actions may differ from those anticipated.
MorphoSys does not intend to update any of these forward-looking statements as
far as the wording of the relevant press release is concerned.


For more information, please contact:

MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122

Mario Brkulj
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454

Jessica Kulpi
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332

investors@morphosys.com


--- End of Message ---

MorphoSys AG
Lena-Christ-Str. 48 Martinsried / München Germany

WKN: 663200;ISIN: DE0006632003;Index:TecDAX,CDAX,Prime All Share,TECH All Share,HDAX,MIDCAP;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;


Press Release (PDF):
http://hugin.info/130295/R/1535145/468071.pdf




This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.

Source: MorphoSys AG via Thomson Reuters ONE

[HUG#1535145]
Related Links: MorphoSys AG
Author:
Hugin
Copyright GlobeNewswire, Inc. 2016. All rights reserved.
You can register yourself on the website to receive press releases directly via e-mail to your own e-mail account.